Staphylococcus aureus bacteraemia
Cross-source consensus on Staphylococcus aureus bacteraemia from 1 sources and 3 claims.
1 sources · 3 claims
Risks & contraindications
Highlighted claims
- Staphylococcus aureus bacteraemia is a severe bloodstream infection with poor outcomes despite active standard antibiotics. — Linezolid in addition to standard antibiotic treatment for Staphylococcus aureus bacteraemia: study protocol for a randomised, placebo-controlled trial
- Mortality after Staphylococcus aureus bacteraemia remains high at 20-30% within 90 days. — Linezolid in addition to standard antibiotic treatment for Staphylococcus aureus bacteraemia: study protocol for a randomised, placebo-controlled trial
- Staphylococcus aureus bacteraemia can spread to secondary body sites and relapse after treatment. — Linezolid in addition to standard antibiotic treatment for Staphylococcus aureus bacteraemia: study protocol for a randomised, placebo-controlled trial